Anti-Rheumatic Drugs - Benelux

Benelux

In Benelux, the revenue in the Anti-Rheumatic Drugs market is anticipated to reach US$0.30bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.00%, leading to a market volume of US$0.30bn by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$34,700.00m in 2024.
In the Benelux region, there is a growing demand for biologic anti-rheumatic drugs as they offer targeted treatment options for patients with rheumatoid arthritis.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Benelux has been on the rise in recent years.

Customer preferences: Patients in Benelux prefer Anti-Rheumatic Drugs that have fewer side effects and are more effective in managing their symptoms. They are also more inclined towards biologic drugs due to their targeted approach and higher efficacy.

Trends in the market: The Anti-Rheumatic Drugs market in Benelux is witnessing a shift towards biologic drugs due to their higher efficacy and targeted approach. This trend is expected to continue in the coming years. Additionally, there has been an increase in the number of biosimilars being introduced in the market, which is expected to increase competition and reduce prices.

Local special circumstances: The healthcare system in Benelux is highly centralized and government-funded. This has resulted in a high level of regulation and price control in the pharmaceutical industry. Additionally, the region has a high prevalence of rheumatoid arthritis, which is driving the demand for Anti-Rheumatic Drugs.

Underlying macroeconomic factors: The aging population in Benelux is a major driver of the Anti-Rheumatic Drugs market as the prevalence of rheumatoid arthritis increases with age. Additionally, the region has a high per capita income, which enables patients to afford expensive biologic drugs. The healthcare system in the region is also highly developed, which ensures that patients have access to the latest treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.